Our take: First time the FDA has greenlighted a marijuana-derived drug... | ------------
The Food and Drug Administration (FDA) made history on Monday: For the first time, it approved the use of a marijuana-derived drug.
The drug, Epidiolex, treats two rare and severe forms of epilepsy in patients ages 2 and older using a purified form of cannabidiol oil (CBD oil), a derivative of cannabis that doesn't result in a high.
GW Pharmaceuticals is producing the drug.
In clinical trials, it reduced seizures in people with Dravet syndrome and Lennox-Gastaut syndrome without the harsh side effects of typical epilepsy drugs, which can include nausea, blurred vision and liver problems.
In a press release, FDA Commissioner Scott Gottlieb, MD, makes clear this is not a sweeping legalization of marijuana in general, or any of its other 80 active chemicals:
Proponents of CBD oil say it brings including better sleep, pain management, and depression relief.
But the number of people who swear by it aside, CBD oil is classified as a Schedule I drug by the Drug Enforcement Administration (DEA), which means it has no medicinal value.
thumbnail courtesy of prevention.com